About us

Our
Vision

A bright future for patients with rare kidney disease

Our
Mission

Transforming the treatment landscape for patients with ADPKD and other rare diseases through novel scientific approaches

our approach

Mironid is currently building and progressing a pipeline of drug development programmes that are targeted at cAMP degrading phosphodiesterase enzymes through clinical development. The goal is to generate novel and differentiated therapies for a range of diseases with high unmet medical need.